Therapeutics News

Zerigo Health announced the launch of Zerigo 2.0 ecosystem, a digital platform that connects health care systems and patients to the management and phototherapy treatment of chronic skin conditions, according to a company press release.

Itch intensity was reduced in patients with chronic kidney disease and moderate to severe pruritus who were treated with oral difelikefalin, according to a study.

The FDA has approved a de novo request for Brella, a noninvasive treatment option for primary axillary hyperhidrosis that utilizes targeted alkali thermolysis technology, Candesant Biomedical announced in a press release.

Topical 20% oxybutynin hydrochloride proved superior to placebo and demonstrated a favorable safety profile in the treatment of primary palmar hyperhidrosis, according to a phase 3 study.

In the treatment of mpox, tecovirimat demonstrates superior toleration compared with other antivirals and may be the preferred treatment option for this disease, according to a study.

Almirall announced its financial results for 2022, which included a core net sales growth of 6.6% driven by its European sales, according to a company press release.

Topical cidofovir 1% was associated with rapid improvement of lesions in a cohort of patients with mpox, according to a study.

Hyperhidrosis is a condition that affects nearly 5% of people, although many go undiagnosed.

Candesant Biomedical announced positive results from its pilot study on the targeted alkali thermolysis patch, an investigational treatment for patients with axillary hyperhidrosis, according to a company press release.

Response-adapted therapy in melanoma, which involves removal of certain immunotherapeutic agents in a combination, can reduce costs without a decrease in efficacy, according to a study.